{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:07:27Z","timestamp":1792112847452,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["SRG2014-00019-FHS"],"award-info":[{"award-number":["SRG2014-00019-FHS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG2015-00230-FHS"],"award-info":[{"award-number":["MYRG2015-00230-FHS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG2016-00005-FHS"],"award-info":[{"award-number":["MYRG2016-00005-FHS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Affiliated Brain Hospital of Guangzhou Medical University","award":["2016YFC0906302"],"award-info":[{"award-number":["2016YFC0906302"]}]},{"name":"Affiliated Brain Hospital of Guangzhou Medical University","award":["2014Y2-00105"],"award-info":[{"award-number":["2014Y2-00105"]}]},{"name":"Affiliated Brain Hospital of Guangzhou Medical University","award":["2015BAI13B02"],"award-info":[{"award-number":["2015BAI13B02"]}]},{"name":"Science and Technology Department of Guangdong Province Major Science and Technology","award":["2016B010108003"],"award-info":[{"award-number":["2016B010108003"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jpsychires.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T17:50:29Z","timestamp":1528221029000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"103","author":[{"given":"Wei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Bin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-E.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3811-2732","authenticated-orcid":false,"given":"Chee H.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor S.","family":"Ungvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-0029","authenticated-orcid":false,"given":"Yu-Tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2018.06.005_bib2","series-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib3","series-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib4","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","article-title":"Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic","volume":"4","author":"Citrome","year":"2011","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4088\/JCP.v66n0818c","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement","volume":"66","author":"Citrome","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis","volume":"26","author":"De Hert","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/cap.2016.0189","article-title":"Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study","volume":"27","author":"Goldman","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0300060517716783","article-title":"Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials","volume":"46","author":"Gu","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib16","series-title":"US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch","first-page":"218","article-title":"Clinical global impression scale. In ECDEU assessment manual for psychopharmacology, revised edn","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib17","series-title":"Cochrane handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib22","series-title":"(lurasidone HCl) Tablets US Prescribing Information","author":"Latuda","year":"2012"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eurpsy.2014.08.001","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","volume":"30","author":"Loebel","year":"2015","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib27","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel","year":"2016","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating-scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/2045125315606027","article-title":"A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia","volume":"5","author":"Potkin","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","article-title":"The file drawer problem and tolerance for null results","volume":"86","author":"Rosenthal","year":"1979","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib38","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/15622975.2015.1126675","article-title":"Serotonin transporter gene polymorphism in eating disorders: data from a new biobank and meta-analysis of previous studies","volume":"17","author":"Solmi","year":"2016","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/1570159X13666150115220221","article-title":"The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis","volume":"13","author":"Thomas","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib41","first-page":"41","article-title":"Schizophrenia","volume":"374","author":"Van","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2018.06.005_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/WNF.0b013e3182aa38c4","article-title":"Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics","volume":"36","author":"Wang","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12888-017-1539-0","article-title":"The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.06.005_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1017\/S0033291717001271","article-title":"Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"48","author":"Zheng","year":"2018","journal-title":"Psychol. Med."}],"updated-by":[{"DOI":"10.1016\/j.jpsychires.2018.08.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000}}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618300979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618300979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:11:30Z","timestamp":1758366690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618300979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":44,"alternative-id":["S0022395618300979"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.06.005","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jpsychires.2018.08.019","asserted-by":"object"}]},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}